PB2509: RED BLOOD CELL PYRUVATE KINASE PROPERTIES IN SICKLE CELL DISEASE – OF MICE AND MEN

Схожі ресурси

• Metabolic blood profile and response to treatment with the pyruvate kinase activator mitapivat in patients with sickle cell disease
  за авторством: Myrthe J. vanDijk, та інші
  Опубліковано: (2024-06-01)
• PI-02: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
  за авторством: VAN DIJK M., та інші
  Опубліковано: (2022-08-01)
• P1501: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
  за авторством: M. J. van Dijk, та інші
  Опубліковано: (2022-06-01)
• 5589320 FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
  за авторством: M.J. van Dijk, та інші
  Опубліковано: (2023-04-01)
• Three-year safety, efficacy, and renal outcomes of mitapivat treatment in sickle cell disease: results from the phase 2 open-label study
  за авторством: Geoffrey Z.L. Kuppens, та інші
  Опубліковано: (2026-02-01)